Particle.news

Download on the App Store

Glioblastoma Patient Set for Experimental Vaccine After Positive NHS Treatment Response

More than £260,000 has been raised toward a £464,000 goal to send Fantis to Munich for a pioneering vaccine trial next week.

Image
Image
Image
Image

Overview

  • Fantis first noticed fleeting sweet “caramel” smells—now identified as mini seizures—before an April 2024 biopsy confirmed inoperable stage 4 IDH-wildtype glioblastoma.
  • He has just finished the NHS’s sole glioblastoma regimen of radiotherapy and chemotherapy, with scans showing a promising early response.
  • His family has raised over £260,000 toward a £464,000 target needed to fund dendritic-cell vaccine therapy in Munich starting next week.
  • They are also exploring alternative protocols abroad, including oncothermia in London, a three-phase immunotherapy trial in Cologne and peptide vaccine treatment in Tübingen.
  • Frustrated by two decades of limited NHS advances for glioblastoma, the family has relied on community donations from Stoke-on-Trent and nationwide supporters to pursue experimental care.